View insider buying and selling activity for Myriad Genetics. During the same quarter last year, the firm posted $0.08 EPS. Myriad Genetics has only been the subject of 1 research reports in the past 90 days. Nebula Genomics offers the most affordable Whole Genome Sequencing! Myriad Genetics has an analyst consensus of Moderate Sell, with a price target consensus of $26.33. Myriad Genetics has generated ($0.35) earnings per share over the last year. On average, analysts give the stock a Sell rating. Click Here to get the full report on Myriad Genetics, Inc. (MYGN) Stock. The high price target for MYGN is $36.00 and the low price target for MYGN is $10.00. Earnings results for SCWorx , Analyst Opinion on SCWorx , Earnings and Valuation of (NASDAQ:WORX), Stock market Insights & financial analysis, Best stock to invest, Investment Idea. Myriad Genetics has received 448 “outperform” votes. Earnings results for LAIX , Analyst Opinion on LAIX , Earnings and Valuation of (NYSE:LAIX), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, © 2020 Designed and developed by Karado Limited, Earnings and Growth Analysis : Myriad Genetics (NASDAQ:MYGN), County Bancorp Inc (NASDAQ:ICBK) Upgraded by Zacks Investment Research to Hold, Metrocity Bankshares Inc (NASDAQ:MCBS) Upgraded by BidaskClub to Hold, Investar Holding Corp (NASDAQ:ISTR) Upgraded by Zacks Investment Research to Buy, Metropolitan Bank Holding Corp (NYSE:MCB) Upgraded by Zacks Investment Research to Buy, First Internet Bancorp (NASDAQ:INBK) Downgraded by Zacks Investment Research to Hold, Analysts Are Pretty Bullish … LM Funding America (NASDAQ:LMFA), Must-See Earnings Estimates SCWorx (NASDAQ:WORX), Analyst Valuation and EPS Growth InVivo Therapeutics (NASDAQ:NVIV), Earnings Scorecard & Analyst Reports Taitron Components (NASDAQ:TAIT), numbers crunched for you before earnings results Second Sight Medical Products (NASDAQ:EYES), Reports First Quarter 2020 Results Mesa Royalty Trust (NYSE:MTR), , Will stock surge before Earnings results? In the past three months, Myriad Genetics insiders have sold more of their company’s stock than they have bought. Myriad Genetics has received a consensus rating of Sell. On average, analysts give the stock a Sell rating. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and KalVista Pharmaceuticals. Metropolitan Bank Holding Corp} stock has undergone multiple analysts rating changes in the recent past. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Myriad Genetics has only been the subject of 1 research reports in the past 90 days. Tecan Group AG (TCHBF) Receives a Hold from Kepler Capital, Medios AG (MEDOF) Gets a Buy Rating from Kepler Capital, Commerzbank AG (CRZBY) was Upgraded to a Buy Rating at Kepler Capital, Deutsche Lufthansa AG (DLAKY) was Upgraded to a Buy Rating at Kepler Capital, Kepler Capital Sticks to Its Buy Rating for Glanbia (GLAPF), A Director at Halozyme (NASDAQ: HALO) is Selling Shares, Trevali Mining (TREVF) Gets a Hold Rating from Raymond James, Analysts Are Bullish on Top Consumer Goods Stocks: Alimentation Couche Tard (ANCUF), BRP (DOOO), A Director at Cyanotech (NASDAQ: CYAN) is Selling Shares, The Senior Vice-President Corporate Development of Westport Fuel Systems (NASDAQ: WPRT) is Selling Shares. Myriad Genetics has a P/B Ratio of 1.48. Wall Street analysts are rating MYGN a Sell today. Jones covers the Healthcare sector, focusing on stocks such as Bio-Techne Corporation, Orasure Technologies, and Pacific Biosciences. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah. Specifically, they have bought $0.00 in company stock and sold $38,639.00 in company stock. node.dataset.value : node.getAttribute('data-value'); if (selectedValue) { for (var j = 0; j < node.options.length; j++) { if(node.options[j].value === selectedValue) { node.options[j].selected = 'selected';break;}}}}}. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.42. In a note to investors, the firm issued a new rating of Hold. Copyright © 2020. How Have the Numbers Shaped Up for Vista Oil & Gas... worth buying post Earnings results? View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Sie können Ihre Einstellungen jederzeit ändern. Dies geschieht in Ihren Datenschutzeinstellungen. The average price target is $13.571, which means analysts expect the stock to decrease by -8.49% over the next twelve months. Myriad Genetics has confirmed that its next quarterly earnings report will be published on Monday, November 9th, 2020. Vote “Underperform” if you believe MYGN will underperform the S&P 500 over the long term. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. First Internet Bancorp Downgraded by Zacks Investment Research on 10/2/2020. 1.9 Community Rank. Get daily stock ideas top-performing Wall Street analysts. The company had revenue of $93.20 million for the quarter, compared to analysts’ expectations of $95.44 million. The company’s average rating score is 1.40, and is based on no buy ratings, 2 hold ratings, and 3 sell ratings. Their average twelve-month price target is $17.00, predicting that the stock has a possible upside of 18.96%. On average, they expect Myriad Genetics' stock price to reach $17.80 in the next year. The company's average rating score is 1.40, and is based on no buy ratings, 2 hold ratings, and 3 sell ratings. Do Not Sell My Personal Information (CA Residents Only). View institutional ownership trends for Myriad Genetics. Portions of this content may be copyrighted by Fresh Brewed Media, Investors Observer, and/or O2 Media LLC. nodes[i].dataset.subscription : nodes[i].getAttribute('data-subscription'); if(status ==='true') {nodes[i].checked = true;}}};var nodes = document.querySelectorAll('#form1783 select[data-value]'); if (nodes) { for (var i = 0; i < nodes.length; i++) { var node = nodes[i]; var selectedValue = node.dataset ? This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings. The P/E ratio of Myriad Genetics is -5.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. This data allows traders to react before numbers are officially reported. Myriad Genetics has a P/B Ratio of 1.16. The average price target is $0.00 In a note to investors, the firm issued a new rating of Hold. View which stocks are hot on social media with MarketBeat's trending stocks report. Starrett , Earnings and Valuation of (NYSE:SCX), Stock market Insights & financial analysis, Best stock to invest, Investment Idea. Damit Verizon Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie bitte 'Ich stimme zu.' In early May several hundred investors, doctors and brokerage research analysts attended a dinner presentation after cocktails offered by the leadership of Myriad Genetics in Manhattan’s midtown. Myriad Genetics has received 62.57% “underperform” votes from our community.